|We have been focusing on the analysis of the proliferation and differentiation of hematopoietic stem cells, particularly on the pathogenesis of hematopoietic tumors such as leukemia, lymphoma, myeloma, and adult T-cell leukemia. Our major goal is to establish new therapeutic modalities targeting specific abnormalities identified in hematopoietic neoplasms. In the research area of rheumatology, we are studying the nature of inflammation seen in systemic autoimmune diseases. We have also been active in the area of AIDS research, in particular, the study and development of novel anti-HIV drugs and the elucidation of the mechanism of HIV drug-resistance. Last year, a novel protease inhibitor, darunavir/TMC114, which we developed, was approved as a prescription drug by the US Food and Drug Administration and has now been used worldwide. One of our recent focuses is on the inhibition of chemokine receptor-mediated cellular entry of HIV, a new modality of intervention of the virus.